Qiagen reveals purchase price for Enzymatics buy; BioFire Diagnostics gets FDA blessing for updated PCR system;

> Qiagen ($QGEN) disclosed in a regulatory filing that it paid $114.2 million in cash to purchase Enzymatics' enzyme unit in December 2014. Filing

> bioMérieux's BioFire Diagnostics division got an FDA nod and European approval for an updated version of its FilmArray PCR molecular diagnostic system, FilmArray 2.0. Statement (PDF)

> Myriad Genetics ($MYGN) is touting promising clinical data for its melanoma test, saying the tool demonstrates 90% accuracy in distinguishing between benign skin moles from malignant melanoma. Statement

> India's Thyrocare Technologies, which touts itself as the "world's largest thyroid testing laboratory," is planning to raise $85 million to $100 million in an IPO by the end of June. Story

> Meridian Bioscience ($VIVO) snagged a CE mark for its new test for Streptococcus pneumoniae in urine and spinal fluid. Release

> Transgenomic priced its public offering, planning to raise $6.2 million in proceeds to fund working capital and general corporate purposes. Filing

> Thermo Fisher Scientific ($TMO) last year took on $155.7 million in charges related to job cuts, the company revealed in a regulatory filing. Filing

> Singapore-based diagnostics outfit Vela Diagnostics is ceasing normal operations, going into judicial management amid financial struggles. More

> Belgium-based OncoDNA inked a distribution agreement with BioSequence, making the latter the exclusive Spanish distributor of OncoDNA's clinical oncology molecular diagnostics. More

And Finally… A lack of conclusive testing for chronic fatigue syndrome could lead to a lack of consensus in the medical community on how to address the disease. Story (sub. req.)

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.